A total of 131 patients were enrolled at 19 leading wound care centers across the United States. Patients between 18 and 80 years of age with confirmed type 1 or type 2 diabetes and chronic diabetic ...

PITTSBURGH, PA--(Marketwired - October 11, 2016) - Net Health, the leading provider of software solutions for specialized outpatient care, announced today that their partnership with Osiris ...

Results were presented from Protocol 302, a multi-center, randomized, controlled study that was conducted to compare the safety and effectiveness of Grafix to standard of care in patients with chronic ...

Grafix closes three times as many wounds as standard of care - the largest relative improvement ever reported in a multi-center, randomized, controlled clinical trial for DFU COLUMBIA, Md.--(BUSINESS ...

COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound ...

NEW YORK (AP) -- Osiris Therapeutics said Friday that Medicare reimbursement rates for outpatient use of its wound care product Grafix should stay the same for about two more years. Shares of Osiris ...

COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (NAS: OSIR) , announced today that its multi-center, randomized, controlled clinical trial evaluating the safety and effectiveness of Grafix ...

A partnership between Osiris Therapeutics and Net Health has broadened the availability of Grafix, a human placental tissue product used to treat chronic wounds. At present, Grafix is marketed by ...

COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (NAS: OSIR) , the leading company focused on developing and marketing stem cell products to treat serious medical conditions, announced today ...

Grafix ® Diabetic Foot Ulcer Clinical Trial Accepted for Presentation at the 2013 Symposium on Advanced Wound Care COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (NAS: OSIR) , announced ...